Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 10773 add-on study in type 2 diabetes mellitus with renal impairment
NL-OMON34610Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in HbA1c after 24 weeks of treatment. Started Jan 2011; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON34610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34610.